All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 4, 2023
Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
Immuno-oncology, BioWorld Science RSS Feed RSS

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.
Immuno-oncology

Pliant's integrin inhibitor PLN-101095 cleared to enter clinic for solid tumors

Feb. 3, 2023
No Comments
Pliant Therapeutics Inc. has received FDA clearance of its IND application for PLN-101095, an oral, small-molecule, dual selective inhibitor of integrins αvβ8 and αvβ1.
Read More
Cancer cells being destroyed by immunotherapy
Immuno-oncology

IND-enabling toxicology studies of Sonnet's SON-1210 in NHPs support progression to clinic

Feb. 2, 2023
No Comments
Sonnet Biotherapeutics Holdings Inc. has completed two IND-enabling toxicology studies in nonhuman primates (NHPs) using its lead bifunctional therapeutic candidate, SON-1210.
Read More
Illustration of antibodies binding to human cell receptors
Immuno-oncology

Ymmunobio signs transfer ownership agreement for license to NPTXR antibodies

Feb. 1, 2023
No Comments
Ymmunobio AG has secured ownership of neuronal pentraxin receptor (NPTXR) antibodies after the company signed a transfer ownership agreement with Nagoya University for a license to NPTXR antibodies.
Read More
Immuno-oncology

Coeptis collaborates with University of Pittsburgh on SNAP-CAR T cells targeting HER2-positive cancers

Feb. 1, 2023
No Comments
Coeptis Therapeutics Holdings Inc. has entered into a sponsored research agreement with the University of Pittsburgh to advance preclinical development of SNAP-CAR T cells targeting HER2, and to explore opportunities to expand the applicability of SNAP-CAR in oncology.
Read More
3D representation of tumor microenvironment
Immuno-oncology

Tumor-intrinsic YTHDF1 drives immune evasion and can be targeted to restore antitumor immunity

Feb. 1, 2023
No Comments
N6-methyladenosine (m6A) is the most common endogenous modification in eukaryotic RNAs. Researchers are starting to understand the impact of changes in m6A levels on cancer mechanisms, including immune evasion.
Read More
Microscopic image of acute myeloid leukemia (AML) cells.
Immuno-oncology

Bivictrix reports promising in vivo data with BVX-001 in CD34-boosted humanized murine model

Feb. 1, 2023
No Comments
Bivictrix Therapeutics plc has released promising...
Read More
Immuno-oncology

Transcode reports preclinical proof-of-mechanism study results with immunotherapy TTX-RIGA

Feb. 1, 2023
No Comments
Transcode Therapeutics Inc. has conducted...
Read More
The epidermal growth factor receptor in the inactive (left) and active (right) form.
Immuno-oncology

Deka's IND for DK-210 (EGFR) in advanced solid cancer receives FDA clearance

Jan. 31, 2023
No Comments
Deka Biosciences Inc.'s IND application has been cleared by the FDA allowing the company to proceed with a phase I trial of DK-210 (EGFR) in patients with advanced solid cancer overexpressing epidermal growth factor receptors (EGFR).
Read More
Antibodies attacking cancer cell
Immuno-oncology

Centessa to advance conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody

Jan. 27, 2023
No Comments
Centessa Pharmaceuticals plc has received clearance of its IND application from the FDA to initiate a first-in-human phase I/IIa trial of LB-101 for the treatment of solid tumors.
Read More
Immuno-oncology

Sana receives IND clearance for CAR T-cell therapy SC-291 for B-cell malignancies

Jan. 27, 2023
No Comments
Sana Biotechnology Inc. has received FDA clearance of its IND application to initiate a first-in-human study of SC-291 in patients with various B-cell malignancies. Initial clinical data from the study are expected later this year. SC-291 is a CD19-targeted allogeneic chimeric antigen receptor (CAR) T-cell therapy developed using Sana's hypoimmune platform.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 876 877 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 3, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Feb. 3, 2022.
  • Setpoint Medical - vagus nerve stimulation device

    Setpoint Medical lands up to $145M to advance RA implant

    BioWorld MedTech
    Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...
  • CFIUS singles out mergers with Chinese companies as potential national security threats

    BioWorld
    Proposed mergers with Chinese companies will likely be subject to increased scrutiny from the Committee on Foreign Investment in the United States (CFIUS) as...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing